

March 6, 2015

Announcement of a patent registration

OncoTherapy Science, Inc. (President & CEO: Masaharu Mori; hereinafter, “OncoTherapy”) announces that OncoTherapy obtained a substance patent in the United States of America for the TOPK (T-LAK cell-originated protein kinase) -specific inhibitors that are being developed by OncoTherapy as novel anti-cancer drugs.

Patent No. 8962648

Country: The United States of America

Title of invention: Tricyclic compounds and PBK inhibitors containing the same

TOPK is one of the novel anti-cancer drug targets identified by the genome-wide gene expression analyses conducted by Professor Yusuke Nakamura’s laboratory. It is highly expressed in various types of human cancer including breast and lung cancers, while its expression was hardly detectable in normal tissues. It is therefore expected that a drug acting on TOPK can be applied to a wide range of human cancers with a minimum risk of adverse side effects.

As announced on October 23, 2014 by OncoTherapy in a release titled “Publication of a manuscript describing the development of a small molecule compound causing complete regression of tumors in mice model”, the collaborative research between OncoTherapy and Professor Yusuke Nakamura’s group at the University of Chicago demonstrated that the small molecule compounds (including OTS964), which inhibit TOPK kinase activity with high activity and selectivity, suppressed the growth of various types of human cancer cells and exhibited significant tumor growth suppression of human lung cancer in a mouse xenograft model. Importantly, intravenous administration of a liposomal formulation of the compound OTS964 as well as oral administration of its free form caused complete regression of human tumors transplanted in mice. In addition, colleagues in Chicago confirmed the TOPK-specific mode of action of the small molecular compounds through the comparison of the results from the xenograft models with the results from the cultured cells. On the basis of these as well as other results that will be obtained from non-clinical studies in the future, OncoTherapy will plan to prepare for clinical trials of the compounds.